+

WO2008032153A3 - Calreticulin for its use as a medication for the treatment of cancer in a mammal - Google Patents

Calreticulin for its use as a medication for the treatment of cancer in a mammal Download PDF

Info

Publication number
WO2008032153A3
WO2008032153A3 PCT/IB2007/002502 IB2007002502W WO2008032153A3 WO 2008032153 A3 WO2008032153 A3 WO 2008032153A3 IB 2007002502 W IB2007002502 W IB 2007002502W WO 2008032153 A3 WO2008032153 A3 WO 2008032153A3
Authority
WO
WIPO (PCT)
Prior art keywords
erp57
crt
calreticulin
anthracyclines
translocation
Prior art date
Application number
PCT/IB2007/002502
Other languages
French (fr)
Other versions
WO2008032153A2 (en
Inventor
Michel Sarkis Obeid
Original Assignee
Michel Sarkis Obeid
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06291427A external-priority patent/EP1900375A1/en
Priority claimed from US11/845,067 external-priority patent/US20090005305A1/en
Priority claimed from US11/845,065 external-priority patent/US20090004134A1/en
Priority claimed from US11/845,063 external-priority patent/US20090004178A1/en
Priority claimed from US11/845,061 external-priority patent/US20090004211A1/en
Priority claimed from US11/845,062 external-priority patent/US20090010952A1/en
Priority claimed from US11/845,060 external-priority patent/US20080214452A1/en
Priority claimed from US11/845,064 external-priority patent/US20090048159A1/en
Priority claimed from US11/845,069 external-priority patent/US20090004678A1/en
Priority claimed from US11/845,068 external-priority patent/US20090004172A1/en
Application filed by Michel Sarkis Obeid filed Critical Michel Sarkis Obeid
Publication of WO2008032153A2 publication Critical patent/WO2008032153A2/en
Publication of WO2008032153A3 publication Critical patent/WO2008032153A3/en
Priority to US12/882,183 priority Critical patent/US20110060120A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Anthracyclines-treated tumor cells are particularly effective in eliciting an anti-cancer immune response, where the rDNA-damaging agents, such as etoposide and mitomycin C do not induce immunogenic cell death. Anthracyclines induce the rapid, pre-apoptotic translocation of calreticulin (CRT) and/or ERP57 to the cell surface. Knock down of CRT and/or ERP57 suppressed the phagocytosis of anthracyclines-treated tumor cells by dendritic cells and abolished their immunogenicity in mammals, such as mice. The anthracyclines-induced CRT and/or ERP57 translocation was mimicked by inhibition of the protein phosphatase 1/GADD34 complex. Administration of recombinant calreticulin, and not recombinant ERP57, or inhibitors of protein phosphatase 1 /GADD34 restored the immunogenicity of cell death elicited by etoposide and mitomycin C, and enhanced their antitumor effects in vivo. These data identify calreticulin and/or ERP57 as a key feature determining anti-cancer immune responses and delineate a possible strategy for immunogenic chemotherapy. This invention demonstrates that calreticulin exposure dictates also sperm-egg fusion. This invention includes also the using of recombinant CRT and/or ERP57 or the inducers of the translocation of CRT and/or ERP57 protein to treat sterility. The detection of the translocation of CRT and/or ERP57 is a good way to screen new immunogenic molecules and compounds.
PCT/IB2007/002502 2006-09-08 2007-08-31 Calreticulin for its use as a medication for the treatment of cancer in a mammal WO2008032153A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US12/882,183 US20110060120A1 (en) 2006-09-08 2010-09-14 Immunogenic treatment of cancer by peptides inducing the plasma membrane exposure of erp57

Applications Claiming Priority (22)

Application Number Priority Date Filing Date Title
EP06291427A EP1900375A1 (en) 2006-09-08 2006-09-08 Calreticulin for its use as a medication for the treatment of cancer in a mammal
EP06291427.0-2107 2006-09-08
US11/774,585 2007-07-07
US11/774,585 US20090005302A1 (en) 2006-09-08 2007-07-07 Method, apparatus, and compound for effecting localized, non-systemic, immunogenic treatment of cancer
US11/845,065 US20090004134A1 (en) 2006-09-08 2007-08-25 Kit for treating a health condition by inducing translocation of an erp57 protein to a cellular membrane
US11/845,063 US20090004178A1 (en) 2006-09-08 2007-08-25 Pharmaceutical compound for blocking the crt or erp57 translocation
US11/845,061 US20090004211A1 (en) 2006-09-08 2007-08-25 Method for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using erp57 translocation
US11/845,062 US20090010952A1 (en) 2006-09-08 2007-08-25 Pharmaceutical compound for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt or erp57 translocation
US11/845,067 US20090005305A1 (en) 2006-09-08 2007-08-25 Service for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt translocation
US11/845,064 2007-08-25
US11/845,060 US20080214452A1 (en) 2006-09-08 2007-08-25 Method for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using crt translocation
US11/845,067 2007-08-25
US11/845,065 2007-08-25
US11/845,061 2007-08-25
US11/845,063 2007-08-25
US11/845,060 2007-08-25
US11/845,064 US20090048159A1 (en) 2006-09-08 2007-08-25 Kit for treating a health condition by inducing translocation of a calreticulin protein to a cellular membrane
US11/845,062 2007-08-25
US11/845,069 US20090004678A1 (en) 2006-09-08 2007-08-26 Method for screening fertility and new compounds or molecules, using crt or erp57 translocation
US11/845,069 2007-08-26
US11/845,068 US20090004172A1 (en) 2006-09-08 2007-08-26 Service for effecting localized, non-systemic and systemic, immunogenic treatment of cancer using erp57 translocation
US11/845,068 2007-08-26

Publications (2)

Publication Number Publication Date
WO2008032153A2 WO2008032153A2 (en) 2008-03-20
WO2008032153A3 true WO2008032153A3 (en) 2008-11-27

Family

ID=39184169

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/002502 WO2008032153A2 (en) 2006-09-08 2007-08-31 Calreticulin for its use as a medication for the treatment of cancer in a mammal

Country Status (1)

Country Link
WO (1) WO2008032153A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2503997B1 (en) 2009-11-23 2017-06-21 INSERM - Institut National de la Santé et de la Recherche Médicale Inhibitors of the pp1/gadd34 complex for the treatment of a condition requiring an immunosuppressive activity
US9801909B2 (en) 2015-04-06 2017-10-31 The Penn State Research Foundation Compositions and methods for combating bacterial infections by killing persister cells with mitomycin C
US10556965B2 (en) 2016-01-28 2020-02-11 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CA3061044A1 (en) * 2017-04-26 2018-11-01 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer
CN111766848B (en) * 2020-06-29 2021-09-10 北京广利核系统工程有限公司 Method and device for verifying failure rate of subsystem in instrument control system

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000020577A1 (en) * 1998-10-06 2000-04-13 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Huuman Services, The National Institutes Of Health Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
WO2002006327A2 (en) * 2000-07-17 2002-01-24 Northwestern University A method for prognosing cancer and the proteins involved
WO2002099061A2 (en) * 2001-06-04 2002-12-12 The Regents Of The University Of Michigan Method of treating alzheimer's disease with se-containing peptide
US20030060613A1 (en) * 1995-01-24 2003-03-27 Shoukat Dedhar Novel use of calreticulin in modulating hormone responsiveness and new pharmaceuticals for treating cancer, osteoporosis and chronic inflammatory disease
WO2003068941A2 (en) * 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
US20040248217A1 (en) * 2002-11-01 2004-12-09 Tatsuhiro Yoshiki Tumor marker for urothelial carcinoma

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030060613A1 (en) * 1995-01-24 2003-03-27 Shoukat Dedhar Novel use of calreticulin in modulating hormone responsiveness and new pharmaceuticals for treating cancer, osteoporosis and chronic inflammatory disease
WO2000020577A1 (en) * 1998-10-06 2000-04-13 The Government Of The United States Of America, Represented By The Secretary, Dept. Of Health And Huuman Services, The National Institutes Of Health Use of calreticulin and calreticulin fragments to inhibit endothelial cell growth and angiogenesis, and suppress tumor growth
WO2002006327A2 (en) * 2000-07-17 2002-01-24 Northwestern University A method for prognosing cancer and the proteins involved
WO2002099061A2 (en) * 2001-06-04 2002-12-12 The Regents Of The University Of Michigan Method of treating alzheimer's disease with se-containing peptide
WO2003068941A2 (en) * 2002-02-13 2003-08-21 Duke University Modulation of immune response by non-peptide binding stress response polypeptides
US20040248217A1 (en) * 2002-11-01 2004-12-09 Tatsuhiro Yoshiki Tumor marker for urothelial carcinoma

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GARDAI S.J. ET AL: "Cell-surface calreticulin initiates clearance of viable apoptotic cells through trans-activation of LRP on the phagocyte.", CELL, vol. 123, 21 October 2005 (2005-10-21), pages 321 - 334, XP002432361 *
JAZOWIECKA-RAKUS J. ET AL.: "Combination of vasotatin gene therapy with cyclophosphamide inhibits growth of B16(F10) melanoma tumours.", ACTA BIOCHIMICA POLONICA, vol. 53, no. 1, January 2006 (2006-01-01), pages 199 - 202, XP002432362 *

Also Published As

Publication number Publication date
WO2008032153A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
Thubagere et al. Nanoparticle-induced apoptosis propagates through hydrogen-peroxide-mediated bystander killing: insights from a human intestinal epithelium in vitro model
Yang et al. Comprehensive lipid profiling of plasma in patients with benign breast tumor and breast cancer reveals novel biomarkers
Messalli et al. Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors
Loo et al. An aptasensor using DNA aptamer and white light common-path SPR spectral interferometry to detect cytochrome-c for anti-cancer drug screening
Tsurutani et al. Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non–small-cell lung cancer tumors
Chinni et al. Akt inactivation is a key event in indole-3-carbinol-induced apoptosis in PC-3 cells
Nury et al. Induction of oxiapoptophagy, a mixed mode of cell death associated with oxidative stress, apoptosis and autophagy, on 7-ketocholesterol-treated 158N murine oligodendrocytes: Impairment by α-tocopherol
Bandyopadhyay et al. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia
Todor et al. The lipid content of cisplatin-and doxorubicin-resistant MCF-7 human breast cancer cells
WO2008032153A3 (en) Calreticulin for its use as a medication for the treatment of cancer in a mammal
Pacheco et al. Docosahexanoic acid antagonizes TNF-α-induced necroptosis by attenuating oxidative stress, ceramide production, lysosomal dysfunction, and autophagic features
Peng et al. Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer
Thanan et al. Inflammation-related DNA damage and expression of CD133 and Oct3/4 in cholangiocarcinoma patients with poor prognosis
Blanco et al. Prognostic significance of N‐glycolyl GM3 ganglioside expression in non‐small cell lung carcinoma patients: New evidences
WO2008103645A3 (en) Prostate cancer and melanoma antigens
Chen et al. Purification and characterization of an antitumor protein with deoxyribonuclease activity from edible mushroom Agrocybe aegerita
Shibata et al. Free fatty acids inhibit protein tyrosine phosphatase 1B and activate Akt
Cífková et al. Correlation of lipidomic composition of cell lines and tissues of breast cancer patients using hydrophilic interaction liquid chromatography/electrospray ionization mass spectrometry and multivariate data analysis
Smith et al. A reliable biomarker derived from plasmalogens to evaluate malignancy and metastatic capacity of human cancers
Zhang et al. Toll-like receptor 2 and Toll-like receptor 4-dependent activation of B cells by a polysaccharide from marine fungus Phoma herbarum YS4108
Raggi et al. Antitumor activity of a novel fibroblast growth factor receptor inhibitor for intrahepatic cholangiocarcinoma
Billimoria et al. Senescence in cancer: Advances in detection and treatment modalities
Bie et al. The immunomodulatory effect of docosahexaenoic acid (DHA) on the RAW264. 7 cells by modification of the membrane structure and function
Huang et al. Levels and enzyme activity of CD73 in primary samples from cancer patients
Mathisen et al. Secretory PLA2-IIA and ROS generation in peripheral mitochondria are critical for neuronal death

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07804858

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07804858

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载